Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

E Keppra® (levetiracetam) Receives Regulatory Approval in Japan

By Pharmaceutical Processing | July 23, 2010

Otsuka Pharmaceutical Co., Ltd. and UCB today announced that UCB Japan has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® (250 mg and 500 mg Tablets). E Keppra® has been approved in Japan as adjunctive therapy in the treatment of partial onset seizures, with or without secondary generalisation, in adult patients with epilepsy, who have not obtained sufficient response to other antiepileptic drugs.

Levetiracetam was originally developed by UCB and is now marketed as Keppra® in over 90 countries worldwide. In Japan, it will be marketed under the brand name, E Keppra®. Otsuka Pharmaceutical and UCB will co-promote E Keppra® in Japan.

“Japan is the second largest pharmaceutical market in the world and it is a significant achievement that we will soon be able to provide E Keppra® for people living with epilepsy in this important country. E Keppra® is the first product from UCB’s own world-leading CNS research and development programme to be marketed in Japan and we look forward to partnering with Otsuka Pharmaceutical for E Keppra® launch while continuing to bring new medicines for people with severe diseases.” said Roch Doliveux, Chief Executive Officer, UCB.

“We are pleased that we will soon be able to deliver this innovative product which has been long awaited by patients and healthcare professionals in Japan. For more than 10 years since its first approval, Keppra® (levetiracetam) has contributed to the treatment of patients with epilepsy in clinical settings. With our co-promotion partner UCB Japan, we will strive to communicate the new value of E Keppra® as an innovative therapeutic option in Japan.” said Taro Iwamoto, president and representative director of Otsuka Pharmaceutical.

Epilepsy is a chronic neurological disorder affecting more than 50 million people worldwide. In Japan, there are approximately one million people living with epilepsy. Epilepsy is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures. There are many different seizure types and epileptic syndromes, and effective classification guides treatment and prognosis.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards